carmen puliafito

We discuss the use of a home based OCT system with artificial intelligence to monitor the treatment of neovascular AMD with Dr. Nancy Holekamp, Professor of Clinical Ophthalmology, Washington University School of Medicine.

We discuss the two year results of the first bispecific agent for the treatment of diabetic macular edema with Dr. John Wells III, from Palmetto Retina Clinic.

We discuss the results of the Kingfisher trail, a study employing broluizumab q4 weeks for the treatment of diabetic macular edema with Dr. Mark Barakat, Assistant Clinical Profess of Ophthalmology, University of Arizona College of Medicine Phoenix.

Join these renowned experts for a panel discussion on how to incorporate into clinical practice the latest treatments for neovascular age-related macular degeneration (nAMD). The panelists will also share the latest outcomes data and their clinical experience using these therapies.

We review the current status of the Ocular Therapeutics TKI sustained release delivery system for treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor of Ophthalmology USC Roski Eye Institute.

We review current status of clinical research on gene therapy for neovascular AMD and diabetic retinopathy with Dr. Allen Ho, Professor of Ophthalmology, Jefferson Medical College and Wills Eye Hospital.

We review long term results of the Port Delivery System for treating neovascular AMD  with Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida.

The fluocinolone implant at 3 years is a useful modality for treating diabetic macular edema. Discussion with Dr. Michael Singer, Adjunct Professor University of Texas at San Antonio.

Discussion of variations in injection volume for treatment of nAMD, DME and MERVO with Roger Goldberg, M.D., M.B.A.,  Bay Area Retina Associates

We discuss the use of the newly approved Susvimo system for sustained delivery of ranibizumab in the treatment of neovascular AMD with Carl Regillo, MD, Professor of Ophthalmology Thomas Jefferson University and Director of the Retina Service at the Wills Eye Hospital.

We discuss the pathophysiology and techniques associated with subchoroidal administration of drugs and gene therapy vectors with James Major, MD, Ph.D., Retina Consultants of Texas and Houston Methodist Hospital.

In our latest update, We discuss clinical and business careers with Pravin Dugel MD, President, of Iveric Bio.

We discuss with Dr.Christoper Reimann of the Cincinnati Eye Institute the results of an early phase clinical trial in which stem cell derived retina pigment epithelial cells are injected into the sub retinal space in the maculas of eyes with geographic atrophy.

We discuss the use of suprachoroidal gene therapy for eyes with diabetic retinopathy without macular edema with Dr. Dennis Marcus, Clinical Professor of Ophthalmology, Medical College of Georgia.

We asked Dr. Mohamed Genead, Chief Medical Officer, Nanoscope Therapeutics to discuss and review the latest developments in optogenetic gene therapy for retinal degenerations. 

We knew that anti-VEGF therapy favorably affected the natural history of moderate or severe  nonproliferation retinopathy. As a result of DRCR network Protocol W, we now know that careful observation with treatment of complications as they develop produces visual acuity results at 2 years similar to prophylactic therapy.

Dr. Dilsher Dhoot discusses patient outcomes in the PANORAMA trial looking at areas of non perfusion.

Dr. Jamie Dananberg, Chief Medical Officer of Unity Biotechnology discusses their strategy of selectively targeting senescent retinal vascular endothelial cells for a more long lasting effect on altering the pathophysiology of diabetic eye disease.